Circadian & mood disruption during months of Arctic/Antarctic darkness — and bright-light phototherapy as a countermeasure
Beyond the Arctic and Antarctic Circles (66.5° latitude), Earth's 23.5° axial tilt keeps the sun continuously below the horizon for part of the year. At research stations, remote communities, and settlements at these latitudes, the loss of the daily light/dark cycle removes the single strongest synchronizing cue — the zeitgeber — that keeps the internal circadian clock aligned to 24 hours.
Polar night occurs wherever the sun's maximum elevation stays below the horizon for at least one full day. It is not a sudden event but a gradient: as a location approaches the pole, days first lose sunrise-to-sunset "true" daylight, then civil twilight (sun 0° to −6°), then nautical twilight (−6° to −12°), and finally astronomical twilight (−12° to −18°) — beyond which the sky is as dark as any moonless night.
At Svalbard (Longyearbyen, ~78°N), polar night runs from late October to mid-February, though a few hours of blue civil twilight persist near midday for much of that period. At research stations near the poles themselves — McMurdo and Amundsen-Scott South Pole Station — the sun disappears for roughly six continuous months, with only starlight, moonlight, and aurora providing any natural illumination.
The human circadian system is coordinated by the suprachiasmatic nucleus (SCN), a paired structure of roughly 20,000 neurons sitting directly above the optic chiasm in the hypothalamus. Each SCN neuron contains a self-sustaining transcription-translation feedback loop (built from clock genes such as CLOCK, BMAL1, PER, and CRY) that oscillates with a period close to, but not exactly, 24 hours.
Because this intrinsic period is imprecise, the SCN needs a daily correction signal to stay locked to the true 24-hour solar day. That correction arrives almost entirely through light: a dedicated population of intrinsically photosensitive retinal ganglion cells (ipRGCs), expressing the photopigment melanopsin, project directly to the SCN via the retinohypothalamic tract — a pathway that is anatomically and functionally separate from the visual pathway used for image formation.
In classic cave and bunker isolation studies (Michel Siffre, 1962 and later), human volunteers deprived of all time cues settled into free-running sleep-wake cycles of roughly 24.5–25 hours — direct evidence that the unaided human clock runs slightly slower than the solar day and depends on light to stay entrained.
When the zeitgeber is removed — as it effectively is during polar night, when only dim artificial indoor lighting (typically 100–500 lux, far below the intensity needed for strong SCN entrainment) reaches the retina — the circadian clock stops being pinned to 24.0 hours and begins to "free-run" according to its own intrinsic period.
This is the first, subtle stage of polar circadian disruption: no acute symptoms yet, but each day the internal clock drifts a small, cumulative amount relative to clock time. That drift compounds day after day through the winter, setting up the desynchronization described in Stage 2.
As weeks of polar darkness accumulate, the small daily drift of a free-running clock adds up into measurable misalignment. Melatonin — the hormonal output of the SCN clock — begins shifting its timing and losing its normal sharp rhythm, cortisol's wake-promoting morning surge blunts, and sleep timing drifts later, all while the retina receives too little blue-enriched light to correct course.
Melatonin is secreted by the pineal gland under direct SCN control, rising in the evening, peaking in the middle of biological night, and falling before habitual wake time. Its onset under dim light conditions — the Dim Light Melatonin Onset (DLMO) — is the most reliable physiological marker of circadian phase used in sleep medicine.
During extended polar darkness without compensating bright-light exposure, DLMO can drift by several hours across a winter season, and — critically — the amplitude of the rhythm itself flattens. Rather than a sharp rise and fall, melatonin secretion becomes lower-amplitude and more smeared across the 24-hour day, weakening the clarity of the signal the rest of the body uses to time sleep, temperature, and hormone release.
Cortisol normally follows a robust circadian pattern — the cortisol awakening response (CAR) — with a sharp rise in the 30–45 minutes after waking, driven partly by light exposure at that transition. This rhythm supports morning alertness and metabolic readiness.
In the absence of a bright morning light cue (because there effectively is no sunrise), the amplitude of the cortisol awakening response blunts. Combined with a flattened melatonin rhythm, this leaves the body without two of its principal daily timing signals, contributing to the fatigue, grogginess, and reduced daytime alertness commonly reported by polar station personnel during midwinter.
Melanopsin-expressing ipRGCs are maximally sensitive to short-wavelength (blue-enriched) light around 480 nm, and require relatively high irradiance — on the order of hundreds to over a thousand lux reaching the eye — to drive a strong SCN resetting signal. Typical indoor lighting during polar night rarely reaches this threshold.
With ipRGC input starved, sleep-onset and wake times drift later day by day, a pattern documented repeatedly in polar station "winter-over" studies (e.g., Palinkas & Suedfeld's long-running research on Antarctic crews), which report measurable phase delays, fragmented sleep, and reduced sleep efficiency accumulating over the dark season — even among psychologically resilient, carefully screened personnel.
Circadian desynchronization does not stay confined to sleep and hormone timing — it cascades into mood. Seasonal Affective Disorder (SAD) is a well-characterized subtype of depression that recurs each winter, driven in large part by exactly the mechanisms established in Stages 1–2: reduced photic input, phase-shifted rhythms, and consequent changes in monoamine neurotransmission.
Positron emission tomography (PET) studies of the serotonin transporter (SERT) — the protein responsible for clearing serotonin from the synapse — show that SERT binding potential is measurably higher in winter than in summer, and rises further with increasing latitude and decreasing daily sunshine duration. Higher SERT activity means serotonin is cleared from synapses faster, leaving less available for postsynaptic signaling.
This provides a direct molecular link between reduced light exposure and the neurotransmitter changes underlying depressive symptoms: less daylight is associated with a serotonergic system tuned toward faster serotonin reuptake, functionally similar to reduced serotonergic tone.
SAD is clinically distinctive because it typically presents with "atypical" depressive features that are nearly the mirror image of classic major depression:
• Hypersomnia — sleeping considerably more than usual, difficulty rising, and persistent daytime sleepiness • Carbohydrate craving and increased appetite, often with winter weight gain • Low energy, heaviness in the limbs (leaden paralysis) • Social withdrawal, low mood, reduced interest in usual activities • Symptoms following a strict seasonal pattern: onset in autumn/early winter, spontaneous remission in spring
This symptom pattern tracks closely with the circadian phase-delay described in Stage 2 — many patients show a delayed melatonin rhythm relative to their sleep schedule, consistent with the "phase shift hypothesis" of SAD first proposed by Norman Rosenthal and colleagues at the NIMH in the early 1980s.
SAD prevalence rises consistently with distance from the equator. Estimates place full-syndrome SAD at roughly 1% in Florida versus approximately 9% in northern New England and Alaska, with an additional, larger fraction of the population experiencing subsyndromal "winter blues" that does not meet full diagnostic criteria but still measurably affects mood and functioning.
SAD is diagnosed roughly four times more often in women than men, with typical age of onset in early adulthood (20s–30s). At true polar latitudes — where the "winter" is not merely short days but literal continuous darkness for weeks or months — both the prevalence and severity of seasonal mood disturbance among wintering personnel are reported to be higher still, making bright light countermeasures an operational necessity, not just a clinical option.
Rosenthal's original 1984 NIMH case series both named Seasonal Affective Disorder and demonstrated, in the same patients, that daily bright artificial light could relieve winter depressive episodes — the founding observation behind modern light therapy.
Bright light therapy is the first-line, best-evidenced treatment for Seasonal Affective Disorder. A dedicated light box delivers an intensity and spectrum far beyond typical indoor lighting, driving the same ipRGC → SCN pathway that natural sunlight would use — supplying the missing zeitgeber directly and, over days to weeks, reversing the desynchronization from Stages 1–3.
A standard light therapy box delivers approximately 10,000 lux of broad-spectrum white or blue-enriched light (roughly 460–480 nm content, matched to melanopsin's peak sensitivity) at a working distance of about 16–24 inches from the face — many hundred-fold brighter than typical room lighting (100–300 lux) and closer to outdoor daylight intensities (10,000–100,000 lux).
At this irradiance, ipRGCs generate a strong, sustained signal along the retinohypothalamic tract to the SCN. Two things happen simultaneously: ongoing melatonin secretion is acutely suppressed (melatonin is exquisitely light-sensitive), and the SCN's internal phase is nudged — the same mechanism, delivered therapeutically, that a natural sunrise would provide.
Light intensity requirements follow a dose-response curve: dim indoor light (~100 lux) has minimal phase-shifting effect, while 10,000 lux for 30 minutes produces a phase shift comparable to 2,500 lux for roughly 2 hours — which is why compact high-intensity boxes are preferred over merely "bright" ambient lighting.
The standard evidence-based protocol calls for:
• Timing: as soon as possible after habitual wake time, ideally within the first hour • Intensity: 10,000 lux (lower-intensity boxes require proportionally longer sessions) • Duration: 20–30 minutes daily at 10,000 lux (up to 45–60 minutes if using a 2,500 lux unit) • Distance and positioning: roughly 16–24 inches from the box, angled slightly off-center so light reaches the retina without needing to stare directly at the source • Consistency: used daily throughout the symptomatic season, not just during acute mood dips
Evening light exposure is deliberately avoided in this protocol, since light late in the day tends to phase-delay the clock — pushing sleep and mood rhythms later rather than correcting the drift accumulated during polar night.
The circadian system's sensitivity to light is not constant across the day — it follows a phase-response curve (PRC). Light exposure in the biological early morning (shortly after the core body temperature minimum, typically a couple of hours before habitual wake time through the morning) produces a phase advance, shifting the clock earlier. Light exposure in the biological evening produces a phase delay, shifting the clock later.
Because polar-night desynchronization typically manifests as a phase delay (the internal clock running later than desired), morning light exposure is specifically chosen to counteract that drift — applying an advancing signal at exactly the part of the cycle where the system is most responsive to it.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Bright Light Box (10,000 lux) | Direct ipRGC/melanopsin activation via retinohypothalamic tract; strong melatonin suppression and phase advance | ||
| Dawn Simulator | Gradually brightening light before waking, mimicking a natural sunrise; gentler, ramped ipRGC activation | ||
| Blue-Light Glasses (evening avoidance) | Filters ~460–480 nm wavelengths in the evening, preventing indoor/screen light from causing further phase delay | ||
| Melatonin Supplementation (low-dose, timed) | Exogenous melatonin taken per the phase-response curve to nudge SCN phase directly | ||
| Exercise Timing (morning aerobic activity) | Non-photic zeitgeber; morning exertion reinforces phase advance and improves mood via independent pathways |
With consistent daily bright light exposure, the circadian system re-synchronizes: melatonin's rhythm sharpens back toward normal amplitude, the sleep-wake phase realigns, and mood measurably lifts. Recovery is not instantaneous — it unfolds over one to two weeks — and must be sustained through a maintenance protocol for the remainder of the polar winter to avoid relapse.
Circadian re-entrainment happens faster than full mood recovery. Phase markers such as DLMO typically begin shifting back toward a normal, earlier, sharper rhythm within the first several days of consistent morning light therapy, since the phase-response mechanism acts directly and immediately on each exposure.
Mood improvement follows with a short lag — clinical trials (notably the work of Michael Terman and colleagues at Columbia) report that patients using a well-timed 10,000 lux protocol typically notice measurable mood improvement within 3–7 days, with a substantial fraction reaching full or near-full remission of depressive symptoms by one to two weeks of consistent use.
Unlike an infection cleared once and for all, the underlying cause of polar-night circadian disruption — the absence of natural daylight — does not go away until the sun returns. Light therapy is therefore a maintenance intervention, not a one-time fix: daily sessions must continue through the full duration of the dark season.
Discontinuing therapy typically leads to relapse, since the zeitgeber deficit that caused the original desynchronization is still present. Polar research stations that operate structured light therapy programs generally build daily light box use into the crew's standard morning routine, alongside scheduled meals and shift changes, precisely so that the "dose" is not left to individual motivation during the most symptomatic weeks of winter.
Long-term Antarctic winter-over research groups report that structured light therapy programs, combined with regular sleep scheduling and morning exercise, measurably reduce the incidence and severity of winter mood disturbance among station crews compared with unstructured exposure to ordinary indoor lighting.
Response to light therapy varies with individual chronotype (natural "morning lark" versus "night owl" tendency), the precise phase relationship between a person's current DLMO and their light exposure timing, and comorbid sleep disorders. Some individuals respond better to earlier sessions, others to slightly later ones — in clinical practice, timing can be fine-tuned against the phase-response curve using a patient's own DLMO measurement.
In practice, the strongest outcomes typically come from combining interventions: morning bright light as the primary corrective signal, consistent sleep-wake scheduling, evening blue-light avoidance to prevent re-delaying the clock, and morning exercise as a complementary non-photic zeitgeber. This combination approach — rather than any single measure alone — is what most reliably carries a polar crew or resident through to the return of the sun.